Physician profile
Mark A Adams
NPI 1275526865
$1,595.98
in general payments reported to CMS, 2019-2025
11 companies · $85.22 in 2025
The $85.22 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,333 · 2020: $21.37 · 2021: $44.34 · 2022: $58.16 · 2023: $31.69 · 2024: $22.31 · 2025: $85.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $1,340.22 | 2019-2025 | |
| Pacira Therapeutics, INC. | $64.10 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $42.18 | 2019-2022 | |
| Organogenesis INC. | $33.92 | 2021-2022 | |
| Kerecis Limited | $22.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Depuy Synthes Sales INC. | $21.37 | 2020 | |
| Heron Therapeutics, INC. | $17.33 | 2023 | Zynrelef |
| Hospira, INC. | $14.36 | 2023 | |
| Convatec INC. | $13.44 | 2019 | |
| Medline Industries LP | $13.38 | 2022 | |
| Fidia Pharma USA INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.